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Streszczenie
Cel: Identyfikacja klinicznych i fizycznych czynników ryzyka popromiennej przetoki pochwowo - odbytniczej u chorych na raka szyjki 
macicy.
Materiał i metodyka: Materiał obejmował grupę 222 kolejnych chorych na inwazyjnego raka szyjki macicy poddaną radykalnej radioter-
apii w latach 1993-1995. Pacjentki podzielono na 2 grupy w zależności od sposobu leczenia, samodzielną radioterapię zastosowano u 140 
chorych, u 82 radioterapię w skojarzeniu z leczeniem chirurgicznym. Dla każdej chorej wyznaczono biologiczna dawkę równoważną (BED) 
w punkcie R1 (wg 38 raportu ICRU) wykorzystując model liniowo kwadratowy. Zastosowano metodę regresji logitowej jedno i wielokrotnej. 
Wyznaczono dawki i krzywe ryzyka popromiennej przetoki pochwowo-odbytniczej oraz iloraz szans dla analizowanych czynników ryzyka. 
Wyniki: Wystąpiło 17 popromiennych przetok pochwowo odbytniczych (7,7%), 4 po leczeniu skojarzonym (4,9%) i 13 (9,3%) po samodziel-
nej radioterapii. Czynnikami ryzyka popromiennej przetoki pochwowo-odbytniczej były: biologiczna dawka równoważna w punkcie R1 oraz 
zastosowanie leczenia chirurgicznego. Nie wykazano istotnego wpływu takich cech jak wiek, stopień zawansowania klinicznego, stopień 
sprawności klinicznej, całkowity czas leczenia, rodzaj i wielkość aplikatorów.
Wnioski: Biologiczna dawka równoważna (BED) w punkcie R1 jest istotnym czynnikiem predykcyjnym ryzyka wystąpienia popromiennej 
przetoki pochwowo - odbytniczej a skojarzenie z leczeniem chirurgicznym istotnie modyfikuje tę zależność.
Słowa kluczowe: późny efekt radioterapii, uszkodzenia popromienne, zależność dawka-efekt, brachyterapia, szyjka macicy.
Ocena dawek ryzyka popromiennej przetoki pochwowo-odbytniczej 
u chorych na raka szyjki macicy
This paper is a shortened version of the PhD Thesis „Rectovaginal fistula risk doses in patients with cervical cancer”
Skrót rozprawy doktorskiej „Ocena dawek ryzyka popromiennej przetoki pochwowo - odbytniczej u chorych na raka szyjki macicy”
Summary
Purpose: To evaluate the incidence and risk factors, both clinical and physical, of the development of a postradiation recto-vaginal fistu-
la in cervical cancer patients.
Materials and methods: A retrospective analysis of 222 consecutive patients receiving radical treatment for invasive cervical cancer at 
the Regional Oncology Centre in Bydgoszcz between 1993 and 1995 has been performed, on 140 patients treated with radiotherapy alone 
and 82 patients who received radiotherapy combined with surgical treatment. The doses and dose rates of brachytherapy were specified 
at point A, the mean dose being 49 and 46 Gy for radiotherapy alone and combined treatment, respectively. External beam irradiation was 
applied in fractions of 1.8-2 Gy, up to a total dose of 44.6 Gy (36 - 50 Gy). The dose and dose rate in the rectum (point R1) were determined 
according to the protocol 38th ICRU, the biological extrapolated dose (BED), using a LQ model, was calculated as a sum of a dose from 
external beam irradiation and brachytherapy.
Results: A total of 17 (7.6 %) recto-vaginal cases of fistulae were found; 13 (9,2%) in patients treated with radiotherapy alone, 4 (4,8%) in 
patients treated with combined treatment. The median latency time was 11.8 months (range 7 to 24). There is a strong association between 
the risk of developing a fistula and the biological extrapolated dose (BED) at point R1. Addition of surgical treatment results in a higher risk 
of complications. Age, clinical stage, hemoglobin level, performance status and the overall treatment time, type and size of applicators were 
not found to have a significant effect on the risk of developing recto-vaginal fistula.
Conclusions: The biological extrapolated dose (BED) at point R1 is an important predictive factor relevant for postradiotherapeutic rec-
tovaginal fistula incidence risk. Surgery is an important factor modifying the postradiotherapeutic rectovaginal fistula incidence risk. No sig-
nificant influence on the fistula incidence risk of such parameters as age, FIGO stage, physical activity, haemoglobin level, overall treatment 
time, type and size of applicators has been demonstrated.
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Table 1. Clinical characteristics of different radiotherapy schedules.
late normal tissue damage in radiotherapy) of being a 
quantal, i.e. all-or-nothing effect, which, moreover, leaves 
little doubt as to its clinical diagnosis.
 The clinical picture of a fistula is easy to identify in 
the retrospective analysis of case histories. Moreover, 
a postradiotherapeutic rectovaginal fistula is a late 
complication, and the risk of its possible occurrence is a 
crucial factor limiting the escalation of radiation doses in 
the effort of increasing therapeutic gain. 
 The relationship between radiation dose and clinical 
effect may be significantly affected by numerous factors. 
The modifying factors may be divided into three categories. 
The first comprises physical parameters of irradiation: 
dose per fraction, interval between fractions, dose rate, 
and overall treatment time. The second category contains 
biological factors which are less well characterized: intrinsic 
radiosensitivity, capacity of regeneration and repair of 
sublethal damage as well as degree of oxygenation and 
redistribution in the cellular cycle. These, in turn, are subject 
to the influence of concomitant diseases, mechanical 
injury, infections and age or various genetic syndromes. 
The last category of modifying factors is constituted by the 
interaction of radiotherapy with other treatment modalities 
Introduction
 The therapeutic ratio is the differential consideration of 
the dose dependence of tumour cure probability and risk 
of late complications. Whereas, local tumour control is 
well defined, late complications are much less so. Since 
in most cases, the severity and, sometimes, the latency 
vary between patients and depend on the radiation dose, 
grading systems have been developed to transform 
analogous data on severity distributions into digital data 
of severe complications frequency [1]. This, however, 
inevitably involves a large degree of subjectivity regarding 
the impact of severe complications on the treated patients’ 
quality of life. In the end, the Holthusen concept of a 
therapeutic ratio as a differential dose dependence makes 
sense only if the clinical impact on an individual patient’s 
quality of life is comparable, local tumour recurrence being 
such a grave consequence that it has to be balanced by 
similarly grave normal tissue damage.
 A grave late complication after cervical cancer 
radiotherapy is a rectovaginal fistula. Moreover, it has, 
for the purpose of scientific analysis, the rare advantage 
(shared only by myelopathy and very few other types of 
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Variable Radiotherapy alone Radiotherapy and surgery All
 Number of patiens 140 (63%) 82 (37%) 222 (100%)
Age [year] (222 pts) 55 (24-80) 50 (27-77) 53 (24-80)
Zubrod
(124 pts)
Io 64 (83%) 46 (97%) 110 (88%)
IIo 12 (15%) 1 (2%) 13 (10%)
IIIo 1 (1%) 0 1 (1%)
IVo 0 0 0
FIGO 
(222 pts)
Io 1 (0,5%) 80 (36%) 81 (36%)
IIo 82 (37%) 2 (1%) 84 (38%)
IIIo 56 (25%) 0 56 (25%)
IVo 1 (0,5%) 0 1 (0,5%)
Histology
(222 pts)
Ca planoepitheliale 133 (60%) 82 (37%) 215 (97%)
Adenocarcinoma 5 (2%) 0 5 (2%)
Others 2 (1%) 0 2 (1%)
Haemoglobin level [mg%](222 pts) 11,7 (5,5-15,2) 12,8 (10,9-16,4) 12,1 (5,5-16,4)
Table 2. Dosimetric characteristics of different radiotherapy schedules.
Variable Radiotherapy alone Radiotherapy and surgery All
Average brachytherapy dose at point A [Gy] 49 (± 4,7) 46 (±5,9) 48,2 (±5,4)
Dose at point R1 normalized to dose at point A [%] 84.8 (±36) 77 (± 20) 82 (±31)
Average external radiation dose at the reference 
point [Gy] 45.1 (±1,5) 42 (±6,5) 44.6 (±3,4)
Average external radiation and brachytherapy dose 
at point R1[Gy]
82 (±18) 54 (±23) 72 (±24)
Overall treatment time [day] 76 (±34) 87 (± 73) 80 (±52)
for the same cancer such as surgery, hyperthermia or 
chemotherapy.
 In the group of 222 patients treated for cervical cancer 
in Bydgoszcz between 1993-1995, we observed 21 
patients who developed rectovaginal fistula, which is an 
unexpectedly high rate of this severe complication. For 
this reason, I investigated the whole cohort of patients who 
were treated in those 3 years for cervical cancer in order 
to determine the influence of potential risk factors such 
as dose distribution, dose fractionation, overall treatment 
time, age and interaction with surgery. The aim of this study 
was to assess incidence risk factors of the development 




 Out of patients admitted to the Department of Oncology 
in Bydgoszcz from 1993 to 1995, 222 consecutive 
patients (aged 25 to 80 years, mean 53 years) were 
diagnosed with cancer of the uterine cervix and included 
in the retrospective study. In every case, the diagnosis of 
carcinoma was based on pathological findings according 
to the current classification of the International Federation 
of Obstetricians and Gynecologists. Eighty-one patients 
had Stage IB disease, 84 Stage II, 56 Stage III and one 
Stage IV. One hundred and forty patients with Stage II, III, 
and IV were treated with radiation alone. Therapy consisted 
of intrauterine brachytherapy and additional external beam 
pelvic radiation (XRT) according to different schedules. In 
Stage III or/and in cases of vaginal neoplasmatic infiltration 
bigger than 4 cm, external beam RT was followed by 
brachytherapy (BRT) in 64 of the 140 patients. The mean 
follow-up of this group was 26 months. Eighty-two out 
of 222 patients (80 stage Ib and 2 stage II) underwent 
combined therapy of irradiation (XRT and BRT) and surgery. 
One woman with Stage IB cancer was unfit for surgical 
treatment due to concomitant diseases and was treated 
with RT alone (Table 1). Therapy consisted of preoperative 
brachytherapy followed by a Wertheim-Meigs operation 
(radical hysterectomy) conducted 6 weeks after the second 
brachytherapy fraction. On the basis of intraoperative 
findings (lymph nodes involvement, macroscopic residual 
tumour and/or neoplasmatic cells in the postoperative 
specimen) thirty-six patients were qualified for additional 
external beam pelvic irradiation. The mean follow up was 
39 months.
Brachytherapy
   Two hundred and fifteen patients were treated with low 
dose rate (LDR) brachytherapy using standard Fletcher 
applicators, and 7 patients using vaginal cylinders with 
intracavital tandem. The brachytherapy schedule consisted 
of two insertions, 10-14 days apart. Dose fractions at point 
A and the rectal point R1 were calculated according to the 
report #38 of ICRU (Table 2).
External irradiation
   External irradiation was delivered with megavoltage units 
(Co-60 machine or 9-MV linear accelerator) using a target 
dose of 1,8-2 Gy per fraction, daily, 5 fractions per week. 
The total dose varied between 36 and 50 Gy (mean 44,9 
Gy). EBRT was applied with a four-field box technique; the 
planning target volume was the tumour, external, internal 
and common iliac lymph nodes. No shields were applied. 
Due to the proximity of point A and point R1 the doses were 
considered to be equal.
 Calculations of the biological extrapolated dose (BED) at 
point R1, resulting from variable dose rates of continuous 
irradiation and variable fractionated doses of external 
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Figure 2. The histogram of latent period of rectovaginal fistula.
Figure 1. The actuarial frequency of rectovaginal fistula. (+ censored, o 
complete).
Figure 3. Dependence of rectovaginal fistula risk and biological 
extrapolated dose (BED) at point R1.
Results
 Actuarial, an overall 5-year survival rate in the populations 
examined in stages I0, II0, III0 were 76.5%, 53.3% and 33%, 
respectively. One woman in stage IV0 died 20 months after 
treatment. Twenty-seven subjects (12%) were diagnosed 
with local relapse, whereas remote metastases were found 
in 19 (9%). 
 Rectovaginal fistulas were observed in 21 patients 
(9.5%). In 4 cases the presence of the fistula coincided 
with histopathologically confirmed failure of local tumour 
control and it was impossible to determine whether 
symptoms were due to a late postradiotherapeutic 
complication or to a recurrence of the neoplastic process. 
The remaining 17 cases were unambiguously classified 
as postradiotherapeutic complications. Complications 
occurred in 4 out of 82 patients (4.9%) treated by 
irradiation, were carried out using a linear-quadratic (LQ) 
formula, taking a dose of 60 Gy of continuous irradiation 
delivered in a total time of 168 hours (0,357 Gy/h) as 
equal to the dose of 60 Gy of external irradiation delivered 
in 30 dose fractions in a total treatment time of 42 days. 
Calculations were based on the following formulas [2] and 
parameters: mono-exponential half time of repair (T1/2) of 
1.5h and an α/β ratio of 3.5 Gy for late complications. 
BEDEBRT=DEBRT •(1+ df /(α/β))   
BEDBTH=DBTHatR1•(1+ DBTHatR1*g /(α/β)) 
    g=2•(µ•t-1+exp(-µ•t))/(µ•t)exp2
    µ=1n2/T1/2
   t   = exposure duration
   df = dose per fraction
  DEBRT=total dose EBRT
  DBTHatR1= total dose BTH at R1 point
 A postradiotherapeutic rectovaginal fistula was 
diagnosed if signs and symptoms of fistula occurred in a 
patient who had not been diagnosed with local relapse or 
absence of local tumour control. Due to the concomitant 
inflammatory process in the uterine system, tumour relapse 
was excluded in each case on the basis of the findings of 
a histopathological examination. 
 In order to evaluate risk factors, a uni- and multifactorial 
logistic regression analysis was employed. The occurrence 
of the complication was a dependent variable, and a 
biological extrapolated dose (BED) at point R1 were 
independent explanatory variables, along with parameters 
such as age, FIGO stage, physical activity, haemoglobin 
level, overall treatment time, length of intracavital tandem, 
size of ovoids, and application of intravaginal cylinder 
combined with tandem. P values less than 0.05 were 
considered statistically significant. For each independent 
variable the odds ratio with lower and upper border of 
95% confidence intervals was calculated. All calculations 
were made using maximum-likehood procedures with 
Statistica’99 software [3].
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radiotherapy combined with surgery, and in 13 out of 140 
(9.3%) subjected to radiotherapy alone. In every patient, 
the fistula developed suddenly without any prodromic 
symptoms. The actuarial 5-year risk of radiation-induced 
rectovaginal fistula was 12.3% (Figure 1). The median time 
to the development of this complication was 11.8 months, 
the latent period ranging from 7 to 24 months since the 
Variable Odds ratio -95%Cl +95%Cl p-value
BEDat R1 1.1 1.0 1.1 0.005
Surgery 43.8 0.2 11116.7 0.03
Performance status 19.4 0.4 1053.6 0.14
FIGO stage 1.3 0.1 25.6 0.87
Age 1.0 0.9 1.1 0.98
Haemoglobin level 0.7 0.3 1.6 0.43
Tandem length 0.5 0.2 1.8 0.32
Ovoid size 0.6 0.1 2.6 0.48
Overall treatment time 1.0 1.0 1.0 0.55
Table 3. Physical and clinical risk factors of rectovaginal fistula multivariate analysis.
Figure 4. Dependence of rectovaginal fistula risk and biological 
extrapolated dose (BED) at point R1 for radiotherapy alone and combined 
with surgery.
start of the treatment (Figure 2). The probability density 
function had a log normal distribution.
 Statistical analysis (Table 3) demonstrated a significant 
correlation between the risk of developing rectovaginal 
Discussion
 The incidence of severe sigmoidovaginal and rectova-
ginal fistulae after radiotherapy for cancer of the uterine 
cervix, as attested by the literature, varies from 0% to 9% 
[4-12]. In our study, the incidence of rectovaginal fistulae as 
a postradiotherapeutic complication was 7.6%. The group 
of our patients provided a basis for identifying clinical and 
physical risk factors. 
 The most important risk factor is the radiation dose at 
point R1. There is some disagreement as to the relevance of 
the dose in this [13-16]. The advantage of using the dose at 
point R1 is that it can easily be identified, precisely defined, 
and has widely been adopted in research on radiation-
induced fistulae. Defining a dose rate at a point where the 
dose gradient from brachytherapy is high carries the risk 
of making errors in dose calculation estimated at about 
10% [17,18]. That error was not taken into account in the 
calculations. The results in the form of dose effect curves 
showing the actuarial risk of a rectovaginal fistula in relation 
to the physical dose at point R1 are illustrated in Figure 5 
and show a characteristic sigmoid shape. For comparison, 
a dose response curve in severe complications, which is a 
broader category, presented by Perez [7], is also shown. 
Although the curves were obtained using different methods, 
graphic evaluation of the risk, a logistic regression model 
and the segmental linear regression analysis suggest that 
the results, in fact, do not differ. Kottmeier [19], Pourquier 
[20], Yudelew [21] and Esche [14] also suggested that in 
the dose range from 75 to 85 Gy a rapid increase in the 
severe complication risk occurs. Unfortunately, statistical 
significance of curve fitting precision was not obtained for 
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fistula and the biological extrapolated dose (BED) at 
point R1. The risk of rectovaginal incidence relative to the 
normalized total dose at point R1 is illustrated by the curve 
in Figure 3. Combined treatment with surgery followed by 
radiotherapy also significantly affected the dose-effect 
relationship as also illustrated in Figure 4. 
 No effect of factors such as age, FIGO stage, physica 
activity, haemoglobin level, overall treatment time, type 
and size of applicators on the fistula development risk was 
observed (Table 2). 
Figure 5. Dependence of rectovaginal fistula risk and total dose at point R1 
for radiotherapy alone and radiotherapy combined with surgery. Additionally 
severe rectal complication risk curve according to Perez.
 Our evaluation of the clinical and physical factors 
modifying the postradiotherapeutic fistula incidence risk 
demonstrated no significant influence of such clinical 
factors as age, FIGO stage, physical activity, haemoglobin 
level, overall treatment time, type and size of applicators. 
Radiation dose and dose distribution are the main risk 
factors for the development of this rare but extremely 
severe complication.
Conclusions
1. The biological extrapolated dose (BED) at point R1 is 
an important predictive factor relevant for postradio-
therapeutic rectovaginal fistula incidence risk.
2. Surgery is an important factor modifying the postradio-
therapeutic rectovaginal fistula incidence risk.
3. No significant influence on the fistula incidence risk of 
such parameters as age, FIGO stage, physical activi-
ty, haemoglobin level, overall treatment time, type and 
size of applicators has been demonstrated.
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